Mekenkamp, Leonie J M <br/><br/>
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.  [electronic resource] 

 -  BMC cancer  Jul 2012 
 - 292 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-12-292  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Cetuximab<br/>Chromosomes, Human, Pair 12--genetics<br/>Clinical Trials, Phase III as Topic<br/>Colorectal Neoplasms--drug therapy<br/>DNA Copy Number Variations<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>MicroRNAs--genetics<br/>Middle Aged<br/>Multicenter Studies as Topic<br/>Multivariate Analysis<br/>Mutation<br/>Neoplasm Metastasis<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Randomized Controlled Trials as Topic<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Treatment Outcome<br/>ras Proteins--genetics